Grifols

On the 20th anniversary of the ALTA Awards, we are proud to announce that the 2024 ALTA Award winners are: 🔹 Dr. Tessa Schneeberger , from Philipps-University of Marburg/Schön Klinik Berchtesgadener Land (Germany) for her research on “Psychological disorders in COPD patients with AATD – prevalence and effects of psychotherapeutic intervention and its impact on quality of life” 🔹 Dr. Benoit Allard from Université de La Réunion (France), for his project “Novel therapeutic strategy with alpha-1-antitrypsin-enriched nanoparticles”. Founded in 2004 the ALTA Awards support annually independent research by young investigators to shape the future of AATD therapy. At Grifols we are committed to pushing the boundaries of scientific knowledge to improve people’s health. For more information 👉 http://spr.ly/6043iOSST #pulmonology #geneticcopd #GrifolsScientificAwards

When someone invests their time in helping others, they deserve the best experience and care. We are thrilled to announce a first step in our journey to enhance donor experience through digital transformation in our more than 300 centers in the U.S. Through our new website, chatbot service and DonorHub™ 3.0 donor app, we are streamlining the donation process and providing our valued donors with a more convenient and engaging experience. We're not just updating our donor digital assets; we're improving the way we connect with donors. Thanks to all our team members involved! See our new website and learn more about donating plasma 👉 http://spr.ly/6042iulIM #PlasmaSourceOfLife

We are redefining healthcare innovation, investing over €1.7 billion in R&D in the last five years, and forging ahead with a diverse portfolio of non-plasma treatments and advanced recombinant technologies. Our commitment to improving patient lives is evident in our key therapeutic areas: immunology, hepatology, intensive care, pulmonology, hematology, neurology, and infectious diseases. Through our three R+D worldwide hubs, with over 1,200 investigators, we're pioneering with plasma-derived and non-plasma treatments, including recombinant proteins and small molecules. Our R&D efforts propel us towards groundbreaking discoveries to shape the future of healthcare. Discover our key therapeutic areas 👉 http://spr.ly/60419m7TN #biopharma #WeareInnovation

Did you know that Grifols has the only accredited Academy for Plasmapheresis in the industry? Ensuring the highest safety standards in plasma donation is one of our paradigms. All donor center team members are trained in up-to-date plasma safety and medical technology. Today we would like you to meet Yvonne Franklin, Operations Supervisor, who explains how we ensure that plasma donation is a comfortable and meaningful experience for our donors. #GrifolsPlasma #GrifolsTeam

Plasma-derived medicines can only be obtained from human plasma. This fact represents a challenge to countries, which have the responsibility to ensure enough plasma is collected to meet the needs of the population. In order to compensate donors for the time and effort invested in the generous act of donating plasma, countries have developed different approaches to compensate them in accordance with their own laws and collection models. Learn more here. 👇 #GrifolsPlasma #PlasmaSourceOfLife

We are pleased to announce that Rahul Srinivasan will be our new Chief Financial Officer. Assuming the role on September 16, he will lead Grifols’ overall financial function including planning, treasury, tax, reporting, and investor relations and sustainability. He will also be responsible for implementing effective cash-flow strategies and driving debt-management plans. Srinivasan succeeds Alfredo Arroyo, who with 17 years of dedicated service to Grifols and having driven pivotal changes has recently decided to retire. For more details, please click below to read the press release. 👉 http://spr.ly/60419R8lt #WeAreHealthcare

We are pleased to announce that Dr. Dr. Fabian Szepanowski of University of Duisburg-Essen, Germany, received the 2024 SPIN Award during the annual congress of the Peripheral Nerve Society (PNS) 2024 held in Montreal, Canada. This award recognizes Dr. Szepanowski's project titled "Exploring the relationship between IVIg and lysophosphatidic acid (LPA) as a potential biomarker in chronic inflammatory demyelinating polyneuropathy (CIDP)." Founded in 2008, the SPIN Program is an annual international award to support young scientists and clinicians with innovative ideas relevant to immunoglobulin research in Neurology. The deadline for submitting nominations for the 2025 SPIN Award will be open starting August 1, 2024. More information here 👉 http://spr.ly/604091wwY #neurology #polyneuropathy #GrifolsScientificAwards

Sometimes, retracing processes in reverse allows us to better understand their complexity and the significance of small actions that set them in motion. The importance of plasma-derived medicines lies in their role. They improve both the life expectancy and quality of life of thousands of people worldwide with rare and potentially life-threatening diseases, for which there are no alternative treatments. But they also serve to treat health problems that can affect amy of us. They are used to control bleeding during surgery and traumas, in the treatment of infections, as well as cardiovascular, neurological, and gestational diseases. It all starts with the generous gesture of a plasma donor. #biotechnology #PlasmaSourceofLife

🏳️🌈 Happy Pride Day! We are committed to building a workplace where diversity is celebrated, and inclusion is the norm. It is not just a matter of representation; it's about creating a sense of belonging for all employees, regardless of their sexual orientation, gender identity, or expression. Join us in building awareness for LGBTQIA+ inclusion in the workplace and beyond. #Pride #Diversity #inclusion #WeAreGrifols

It has been an incredible week at #ISBTBarcelona, the team has been buzzing with insights and experiences. We're incredibly grateful for the opportunity to connect with so many inspiring people, both familiar faces and new connections. The chance to build synergies and collaborate was invaluable. We would like to especially thank our speakers for their exceptional presentations on blood typing solutions covering our latest innovations to the Immunohematology field, and on donor screening, addressing the latest emerging pathogens that are putting blood safety at risk. Thank you again to ISBT and everyone who contributed to making #GrifolsISBT such a success. We look forward to reconnecting next year in Milan! #transfusionmedicine #GrifolsISBT